Prevention of recurrence undergoing additional intravesical therapy with pirarubicin for non-muscule invasive bladder cancer.
Phase 2
- Conditions
- on-muscle invasive bladder cancer (intermediate-risk patients)
- Registration Number
- JPRN-UMIN000009967
- Lead Sponsor
- Department of Urology Kobe university graduate school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Active multiple cancers (2) Patients with historically or presently disease of upper urinary tract urothelial cell carcinoma. (3) Target at BCG therapy (unrelated 2nd TUR) (4) Funcion of all organs are without severe dysfunction. (5) Lymph node metastasis or ogan metastasis (6) After TURBT,patients who didn`t undergo intravesical therapy with pirarubicin. (7) Patients who previously underwent intravesical therapy with BCG. (8) Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Duration of recurrence-free survival
- Secondary Outcome Measures
Name Time Method Two-year recurrence free survival rate Safty